TANOVEA-CA1 is the first lymphoma treatment for dogs that has been conditionally approved by the FDA. Targeting rapidly multiplying lymphoma cells, it mimics a DNA building block, preventing cells from dividing and ultimately causing them to die. The medication is convenient (requiring just five office visits) and generally well tolerated. In clinical trials, 77 percent of dogs with lymphoma responded to treatment with TANOVEA-CA1, even those that had stopped responding to other medications. Watch our video below to learn more about the treatment.
Watch on YouTube https://youtu.be/F9HjspUEkyA